This antibiotic works by inhibiting the target DNA pol III alpha, an enzyme present in all bacteria and essential for their growth; this target is absent in humans. CAM-1 was tested against more than 250 different bacterial strains and effectively killed 100% of all drug resistant Staph. aureus, including MRSA, according to the company. Galapagos plans to initiate trials in the first quarter 2014.
"Selection of a candidate antibiotic in our MRSA development program is an important step toward realizing the full potential of our unique anti- bacterial program," said Dr. Piet Wigerinck, chief scientific officer of Galapagos. "Our antibiotics have a novel mode of action which brings all tested MRSA strains to a complete halt. Combined with a diagnostic test, these compounds could bring a real solution to MRSA infections."